Long-term health outcomes of people living with spina bifida
Closed Posted
- Opportunity number
- CDC-RFA-DD-26-0222
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Applications due
- Award size
- $100,000 to $300,000
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- State Governments
- City/Township Governments
- Higher Education Inst. (Private)
- Small Businesses
- County Governments
- 501(c)(3) Nonprofits
- Independent School Districts
- Special District Governments
- Non-501(c)(3) Nonprofits
- Tribal Governments (Federally Recognized)
- For Profit Organizations
- Higher Education Inst. (Public)
- Points of contact
-
- Stephanie Griswold eut6@cdc.gov
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention is soliciting cooperative agreement applications to collect longitudinal health outcome data on children and adults with spina bifida and to implement and evaluate a urologic management protocol for infants and young children with myelomeningocele, with applications due October 26, 2026. The opportunity comprises two components with separate award tracks: Component A funds 8–11 awards to collect high-quality longitudinal data through the National Spina Bifida Patient Registry (NSBPR) at specialized spina bifida clinics; Component B funds 6–8 awards to implement and evaluate the Urologic Management to Preserve Initial Renal Function Protocol for Young Children with Spina Bifida (UMPIRE) and to finalize the protocol for children aged 0–10 with myelomeningocele.
Eligible applicants include state and local governments, higher education institutions (public and private), 501(c)(3) and non-501(c)(3) nonprofits, small businesses, for-profit organizations, independent school districts, special district governments, and federally recognized tribal governments. Component A awards range from $100,000 to $200,000 annually; Component B awards range from $50,000 to $100,000 annually. The period of performance is three years in 12-month budget periods, with an expected award date of August 1, 2027, and start date of September 1, 2027.
Recipients must collect and manage standardized longitudinal data, submit monthly data with limited identifiers to CDC, participate in data quality checks and collaborative analysis activities, and attend annual and quarterly meetings. Applicants must demonstrate organizational capacity including experience with longitudinal data collection, data management infrastructure, staffing with dedicated data coordinators and analysts (and a pediatric urologist for Component B), and letters of commitment from participating clinics documenting access to spina bifida patients. Responsiveness requires documentation of patient enrollment and follow-up visit rates between January 2020 and August 2024, with Component A requiring at least 300 enrolled patients and Component B requiring at least 20 patients with myelomeningocele. The opportunity is funded under Assistance Listing 93.073 (Birth Defects and Developmental Disabilities—Prevention and Surveillance).
Synopsis
The purpose of component A (8-11 awardees) of this NOFO is to collect high-quality longitudinal data on children and adults with spina bifida (SB) who receive care in specialized spina bifida clinics participating in the National Spina Bifida Patient Registry (NSBPR). The purpose of component B (6-8 awardees) is to implement and evaluate the Urologic Management to Preserve Initial Renal Function Protocol for Young Children with Spina Bifida (UMPIRE) iterative protocol which aims to improve the management of the urinary and kidney systems in infants and young children with myelomeningocele. Building on existing longitudinal data collection, recipients will continue to collect data on patients with SB to better understand health outcomes after interventions and treatments, analyze the data and share findings to identify opportunities for improvement of care. An additional objective for Component B is to finalize the UMPIRE protocol for children 0-10 years old with myelomeningocele. Sources of data are specialty clinics that care for pediatric and adult patients with SB
Files
| File | Type | Posted |
|---|---|---|
| cdc-rfa-dd-26-0222_forPublication.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity